logo-loader
viewGenprex, Inc.

Full interview: Genprex makes key hires to its board and executive team

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive the gene therapy group has made a few key hires despite the economic downturn due to the coronavirus.

Varner says the biotech has bolstered its board with three new directors, in addition to appointing two life sciences executives, as the firm advances its lead drug candidate into key clinical programs and pursues partnerships for its cancer platform and newly licensed gene therapy technology for diabetes.

Quick facts: Genprex, Inc.

Price: 3.65 USD

NASDAQ:GNPX
Market: NASDAQ
Market Cap: $141 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genprex, Inc. named herein, including the promotion by the Company of Genprex, Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Genprex reveals slew of recent milestones as it plans for upcoming clinical...

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner talks to Proactive's Christine Corrado about the Texas-based biotechnology company's most recent updates. Namely, Varner says the firm has approved the generic name quaratusugene ozeplasmid, for its non-small cell lung cancer drug formerly known as...

on 07/02/2020

2 min read